MedPath

Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

Not Applicable
Not yet recruiting
Conditions
Major Depressive Disorder (MDD)
Rumination
Interventions
First Posted Date
2025-04-22
Last Posted Date
2025-04-22
Lead Sponsor
Not specified
Target Recruit Count
60
Registration Number
NCT06937476

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

Phase 2
Recruiting
Conditions
MDD
Interventions
Drug: LV232 40mg
Drug: Placebo
Drug: LV232 60mg
First Posted Date
2025-02-17
Last Posted Date
2025-04-24
Lead Sponsor
Vigonvita Life Sciences
Target Recruit Count
400
Registration Number
NCT06828887
Locations
🇨🇳

Shanghai Mental Health Center Ethics Committee, Shanghai, China

Neuroimaging of Escitalopram in Autism Spectrum Disorder

Phase 2
Not yet recruiting
Conditions
Autism Spectrum Disorder
Interventions
First Posted Date
2025-02-13
Last Posted Date
2025-04-03
Lead Sponsor
Kathryn Unruh
Target Recruit Count
5
Registration Number
NCT06826326
Locations
🇺🇸

Hoglund Biomedical Imaging Center, Kansas City, Kansas, United States

RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD

Not Applicable
Completed
Conditions
Major Depression
Interventions
Drug: XingpiJieyu formula
Drug: Placebo
First Posted Date
2025-01-03
Last Posted Date
2025-01-03
Lead Sponsor
Peking University Sixth Hospital
Target Recruit Count
150
Registration Number
NCT06758167
Locations
🇨🇳

Peking University Sixth Hospital, Beijing, Beijing, China

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Phase 2
Not yet recruiting
Conditions
Major Depressive Disorder
Mild Neurocognitive Disorder
HIV
Interventions
First Posted Date
2024-11-26
Last Posted Date
2025-02-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
186
Registration Number
NCT06705478
Locations
🇺🇸

Alabama CRS, Birmingham, Alabama, United States

🇺🇸

University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States

🇺🇸

UCSD Antiviral Research Center CRS, San Diego, California, United States

and more 36 locations

Effort and Antidepressant Study Test

Phase 1
Not yet recruiting
Conditions
Effort Based Decision Making
Prosocial Behavior
Apathy
Interventions
Drug: Placebo 10 mg
First Posted Date
2024-11-20
Last Posted Date
2024-11-20
Lead Sponsor
University of Oxford
Target Recruit Count
50
Registration Number
NCT06696482

Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients with Major Depressive Disorder

Not Applicable
Recruiting
Conditions
Major Depressive Disorder (MDD)
Depression - Major Depressive Disorder
Interventions
First Posted Date
2024-11-18
Last Posted Date
2025-03-11
Lead Sponsor
Gang Wang
Target Recruit Count
214
Registration Number
NCT06692361
Locations
🇨🇳

Wuhu Fourth People's Hospital, Wuhu, Anhui, China

🇨🇳

Beijing Anding Hospital, Beijing, Beijing, China

🇨🇳

The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 4 locations

A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

Phase 1
Active, not recruiting
Conditions
Central Nervous System
Insomnia
Interventions
Drug: YZJ-1139 tablets
Drug: YZJ-1139 simulated tablets
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Target Recruit Count
24
Registration Number
NCT06680531
Locations
🇨🇳

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People

First Posted Date
2024-11-05
Last Posted Date
2024-11-05
Lead Sponsor
Medical University of Vienna
Target Recruit Count
120
Registration Number
NCT06675851
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET

Phase 1
Recruiting
Conditions
Major Depressive Disorder
Interventions
Drug: LV232 40mg
Drug: LV232 60mg
Drug: LV232 20mg
First Posted Date
2024-06-26
Last Posted Date
2025-02-28
Lead Sponsor
Vigonvita Life Sciences
Target Recruit Count
16
Registration Number
NCT06476509
Locations
🇨🇳

Shanghai Mental Health Center Ethics Committee, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath